Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

Amanda Przespolewski; Monica R. Muppidi; Craig W. Freyer; Wenyan Ji; Tara L. Cronin; Swapna Thota; Elizabeth A. Griffiths; James E. Thompson; Evelena P. Ontiveros; Jeffrey Baron; Amro Elshoury; Eunice S. Wang

doi:10.1080/10428194.2021.1885654

Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

Amanda Przespolewski
, Monica R. Muppidi
, Craig W. Freyer
, Wenyan Ji
, Tara L. Cronin
, Swapna Thota
, Elizabeth A. Griffiths
, James E. Thompson
, Evelena P. Ontiveros
, Jeffrey Baron
, Amro Elshoury
, Eunice S. Wang

Office of Research Compliance

University at Buffalo

Roswell Park Cancer Institute
New York City Health + Hospitals
University of Pennsylvania
Cancer Care Specialists of Illinois

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	1778-1781
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	62
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2021.1885654
State	Published - 2021

Access to Document

10.1080/10428194.2021.1885654

Cite this

Przespolewski, A., Muppidi, M. R., Freyer, C. W., Ji, W., Cronin, T. L., Thota, S., Griffiths, E. A., Thompson, J. E., Ontiveros, E. P., Baron, J., Elshoury, A., & Wang, E. S. (2021). Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leukemia and Lymphoma, 62(7), 1778-1781. https://doi.org/10.1080/10428194.2021.1885654

@article{46af2f2d65d14343a762474def863444,

title = "Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy",

author = "Amanda Przespolewski and Muppidi, \{Monica R.\} and Freyer, \{Craig W.\} and Wenyan Ji and Cronin, \{Tara L.\} and Swapna Thota and Griffiths, \{Elizabeth A.\} and Thompson, \{James E.\} and Ontiveros, \{Evelena P.\} and Jeffrey Baron and Amro Elshoury and Wang, \{Eunice S.\}",

year = "2021",

doi = "10.1080/10428194.2021.1885654",

language = "English",

volume = "62",

pages = "1778--1781",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

Przespolewski, A, Muppidi, MR, Freyer, CW, Ji, W, Cronin, TL, Thota, S, Griffiths, EA, Thompson, JE, Ontiveros, EP, Baron, J, Elshoury, A & Wang, ES 2021, 'Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy', Leukemia and Lymphoma, vol. 62, no. 7, pp. 1778-1781. https://doi.org/10.1080/10428194.2021.1885654

Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. / Przespolewski, Amanda; Muppidi, Monica R.; Freyer, Craig W. et al.
In: Leukemia and Lymphoma, Vol. 62, No. 7, 2021, p. 1778-1781.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

AU - Przespolewski, Amanda

AU - Muppidi, Monica R.

AU - Freyer, Craig W.

AU - Ji, Wenyan

AU - Cronin, Tara L.

AU - Thota, Swapna

AU - Griffiths, Elizabeth A.

AU - Thompson, James E.

AU - Ontiveros, Evelena P.

AU - Baron, Jeffrey

AU - Elshoury, Amro

AU - Wang, Eunice S.

PY - 2021

Y1 - 2021

UR - https://www.scopus.com/pages/publications/85100925689

U2 - 10.1080/10428194.2021.1885654

DO - 10.1080/10428194.2021.1885654

M3 - Letter

C2 - 33593230

SN - 1042-8194

VL - 62

SP - 1778

EP - 1781

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

Access to Document

Other files and links

Fingerprint

Cite this